Compare RHI & ARQT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RHI | ARQT |
|---|---|---|
| Founded | 1948 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 3.3B |
| IPO Year | N/A | 2020 |
| Metric | RHI | ARQT |
|---|---|---|
| Price | $28.24 | $30.12 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 6 | 7 |
| Target Price | ★ $36.00 | $24.83 |
| AVG Volume (30 Days) | 1.8M | ★ 1.8M |
| Earning Date | 01-28-2026 | 02-24-2026 |
| Dividend Yield | ★ 8.47% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.54 | N/A |
| Revenue | ★ $5,458,499,000.00 | $317,929,000.00 |
| Revenue This Year | N/A | $85.51 |
| Revenue Next Year | $0.94 | $30.74 |
| P/E Ratio | $18.07 | ★ N/A |
| Revenue Growth | N/A | ★ 129.21 |
| 52 Week Low | $25.22 | $11.13 |
| 52 Week High | $72.10 | $31.77 |
| Indicator | RHI | ARQT |
|---|---|---|
| Relative Strength Index (RSI) | 57.94 | 57.63 |
| Support Level | $26.53 | $28.75 |
| Resistance Level | $28.26 | $30.60 |
| Average True Range (ATR) | 0.82 | 1.22 |
| MACD | 0.07 | -0.04 |
| Stochastic Oscillator | 75.82 | 82.16 |
Robert Half Inc was founded in 1948, Robert Half provides temporary, permanent, and outcome-based staffing for both in-person and remote positions in the finance and accounting, technology, legal, marketing, and administrative fields. Its subsidiary consulting arm, Protiviti, specializes in technology, risk, auditing, and compliance matters. The firm generates its sales inside the U.S. and is one of the specialized firms in the fragmented U.S. staffing industry. The firm generates annual revenue of around $7 billion.
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.